UroGen Mengumumkan Hasil dari ATLAS yang Menunjukkan Durabilitas Respon UGN-102 yang Kuat pada Kanker Kandung Kemih Non-Muscle Invasive Tingkat Rendah Risiko Menengah yang Baru dan Berulang di AUA 2024
…successfully commercialize UGN-102 and other products in development; the potential impact of COVID-19 on UroGen’s clinical trials, preclinical studies, supply chain and other business operations; and other factors discussed in the “Risk Factors” section of UroGen’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, as well as discussions of … Baca Selengkapnya